Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STC-15 in Advanced Malignancies
NCT05584111Phase 1Completed
- Sponsor
- STORM Therapeutics
- Start
- Nov 2022
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of STC-15 in solid tumor (advanced stage) (5 arms), sponsored by STORM Therapeutics. Primary endpoints: Number of participants with adverse events, Maximum Plasma Concentration (Cmax) and 8 more. Started Nov 2022; status: completed.
02
Drugs
STC-15
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05584111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05584111.